Skip to main content
Erschienen in: Endocrine 3/2019

20.07.2019 | Original Article

Unusual metastases from differentiated thyroid carcinoma: analysis of 36 cases

verfasst von: Anabela Zunino, Fabián Pitoia, Eduardo Faure, Adriana Reyes, Mónica Sala, Rosana Sklate, Verónica Ilera, Inés Califano, on behalf of the Thyroid Department of Sociedad Argentina de Endocrinología y Metabolismo

Erschienen in: Endocrine | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Metastases of differentiated thyroid cancer (DTC) in sites different from lungs and bone are unusual (UM); their impact in management and prognosis remains unknown. Our aim was to evaluate the prevalence of UM, to describe their characteristics and to analyze their impact in disease outcome and mortality.

Methods

We retrospectively reviewed the file records from 8 different centers. Those patients with DTC and UM were included. UM were diagnosed by: (i) biopsy/cytology and/or (ii) radioiodine (RAI) uptake associated to elevated thyroglobulin (Tg) levels and/or c) presence of one or more structural lesion/s with 18-FDG uptake in the PET/CT scan and elevated Tg levels.

Results

Thirty-six (0.9%) out of a total of 3982 DTC patients were diagnosed with UM; 75% had papillary histology. The most frequent localization was central nervous system (CNS, 31%). UM were metachronous in 75%, symptomatic in 55.6% and fulfilled RAI-refractoriness criteria in 77.8% of cases. Metastatic lesions in lung/bone and/or locoregional disease were present in 34 cases (94.4%). Diagnosis of UM changed the therapeutic approach in 72.2% of patients. After a median follow up of 13 months, 21 (58.3%) patients died from DTC related causes. In 8 of them CNS progression was the immediate cause of death.

Conclusions

Prevalence of UM was low; they were frequently metachronic and RAI-refractory. Although UM were found in patients with widespread disease, their diagnosis usually led to changes in therapy. UM were associated with poor prognosis and high frequency of disease-specific mortality.
Literatur
1.
Zurück zum Zitat T.P. Links, Life expectancy in differentiated thyroid cancer: a novel approach to survival analysis. Endocr. Relat. Cancer 12(2), 273–280 (2005)CrossRefPubMed T.P. Links, Life expectancy in differentiated thyroid cancer: a novel approach to survival analysis. Endocr. Relat. Cancer 12(2), 273–280 (2005)CrossRefPubMed
2.
Zurück zum Zitat B.R. Haugen, 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid 26(1), 1–133 (2016)CrossRefPubMedPubMedCentral B.R. Haugen, 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid 26(1), 1–133 (2016)CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat J.M. Mihailovic, Metastatic differentiated thyroid carcinoma: clinical management and outcome of disease in patients with initial and late distant metastases. Nucl. Med Commun. 30(7), 558–564 (2009)CrossRefPubMed J.M. Mihailovic, Metastatic differentiated thyroid carcinoma: clinical management and outcome of disease in patients with initial and late distant metastases. Nucl. Med Commun. 30(7), 558–564 (2009)CrossRefPubMed
4.
Zurück zum Zitat A. Leite, 2017 Deaths related to differentiated thyroid cancer: a rare but real event. Arch. Endocrinol. Metab. 61(3), 222–227 (2017)CrossRefPubMed A. Leite, 2017 Deaths related to differentiated thyroid cancer: a rare but real event. Arch. Endocrinol. Metab. 61(3), 222–227 (2017)CrossRefPubMed
5.
Zurück zum Zitat Y. Kitamura, Immediate causes of death in thyroid carcinoma: clinicopathological analysis of 161 fatal cases. J. Clin. Endocrinol. Metab. 84, 4043–4049 (1999)CrossRefPubMed Y. Kitamura, Immediate causes of death in thyroid carcinoma: clinicopathological analysis of 161 fatal cases. J. Clin. Endocrinol. Metab. 84, 4043–4049 (1999)CrossRefPubMed
6.
Zurück zum Zitat I.J. Nixon, The impact of distant metastases at presentation on prognosis in patients with differentiated thyroid carcinoma of the thyroid gland. Thyroid 22(9), 884–889 (2012)CrossRefPubMedPubMedCentral I.J. Nixon, The impact of distant metastases at presentation on prognosis in patients with differentiated thyroid carcinoma of the thyroid gland. Thyroid 22(9), 884–889 (2012)CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat H. Kim, Prognosis of differentiated thyroid carcinoma with initial distant metastasis: a multicenter study in Korea. Endocrinol. Metab. 33, 287–295 (2018)CrossRef H. Kim, Prognosis of differentiated thyroid carcinoma with initial distant metastasis: a multicenter study in Korea. Endocrinol. Metab. 33, 287–295 (2018)CrossRef
8.
Zurück zum Zitat A. Madani, Rare metastases of well-differentiated thyroid cancers: a systematic review. Ann. Surg. Oncol. 22, 460–466 (2015)CrossRefPubMed A. Madani, Rare metastases of well-differentiated thyroid cancers: a systematic review. Ann. Surg. Oncol. 22, 460–466 (2015)CrossRefPubMed
9.
Zurück zum Zitat E. Farina, Unusual thyroid carcinoma metastases: a case series and literature review. Endocr. Pathol. 27(1), 55–64 (2016)CrossRefPubMed E. Farina, Unusual thyroid carcinoma metastases: a case series and literature review. Endocr. Pathol. 27(1), 55–64 (2016)CrossRefPubMed
10.
Zurück zum Zitat M.B. Amin, S. Edge, F. Greene, D.R. Byrd, R.K. Brookland, M.K. Washington, J.E. Gershenwald, C.C. Compton, K.R. Hess, D.C. Sullivan, J.M. Jessup, J.D. Brierley, L.E. Gaspar, R.L. Schilsky, C.M. Balch, D.P. Winchester, E.A. Asare, M. Madera, D.M. Gress, L.R. Meyer AJCC Cancer Staging Manual, 8th edn. (Springer, New York, 2017) M.B. Amin, S. Edge, F. Greene, D.R. Byrd, R.K. Brookland, M.K. Washington, J.E. Gershenwald, C.C. Compton, K.R. Hess, D.C. Sullivan, J.M. Jessup, J.D. Brierley, L.E. Gaspar, R.L. Schilsky, C.M. Balch, D.P. Winchester, E.A. Asare, M. Madera, D.M. Gress, L.R. Meyer AJCC Cancer Staging Manual, 8th edn. (Springer, New York, 2017)
11.
Zurück zum Zitat F. Pitoia, Consenso intersocietario sobre tratamiento y seguimiento de pacientes con cáncer diferenciado de tiroides. Inter Society Consensus for the Management of Patients with Differentiated Thyroid Cancer. Rev. Arg. Endocrinol. Metab. 51(2), 85–118 (2014) F. Pitoia, Consenso intersocietario sobre tratamiento y seguimiento de pacientes con cáncer diferenciado de tiroides. Inter Society Consensus for the Management of Patients with Differentiated Thyroid Cancer. Rev. Arg. Endocrinol. Metab. 51(2), 85–118 (2014)
12.
Zurück zum Zitat M. Schlumberger, Definition and management of radioactive iodine- refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol. 2(5), 356–358 (2014)CrossRefPubMed M. Schlumberger, Definition and management of radioactive iodine- refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol. 2(5), 356–358 (2014)CrossRefPubMed
13.
Zurück zum Zitat D. Hirsch, 2017 Long term outcomes and prognostic factors in patients with differentiated thyroid cancer and distant metastases. Endocr. Pr. 23(10), 1193–1200 (2017)CrossRef D. Hirsch, 2017 Long term outcomes and prognostic factors in patients with differentiated thyroid cancer and distant metastases. Endocr. Pr. 23(10), 1193–1200 (2017)CrossRef
14.
Zurück zum Zitat C. Durante, Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J. Clin. Endocrinol. Metab. 91(8), 2892–2899 (2006)CrossRefPubMed C. Durante, Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J. Clin. Endocrinol. Metab. 91(8), 2892–2899 (2006)CrossRefPubMed
15.
Zurück zum Zitat R. Elisei, Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. J. Clin. Endocrinol. Metab. 95, 1516–1527 (2010)CrossRefPubMed R. Elisei, Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. J. Clin. Endocrinol. Metab. 95, 1516–1527 (2010)CrossRefPubMed
16.
Zurück zum Zitat G. Grani, Follicular thyroid cancer and Hürthle cell carcinoma: challenges in diagnosis, treatment and clinical management. Lancet Diabetes Endocrinol. 6(6), 500–514 (2018)CrossRefPubMed G. Grani, Follicular thyroid cancer and Hürthle cell carcinoma: challenges in diagnosis, treatment and clinical management. Lancet Diabetes Endocrinol. 6(6), 500–514 (2018)CrossRefPubMed
17.
Zurück zum Zitat B. Henriques de Figueiredo, Brain metastases from thyroid carcinoma: a retrospective study of 21 cases. Thyroid 24(2), 270–276 (2014)CrossRefPubMed B. Henriques de Figueiredo, Brain metastases from thyroid carcinoma: a retrospective study of 21 cases. Thyroid 24(2), 270–276 (2014)CrossRefPubMed
18.
Zurück zum Zitat H.S. Lee, Clinical characteristics and follow-up of intracranial metastases from thyroid cancer. Acta Neurochir. (Wien.) 157(12), 2185–2194 (2015)CrossRef H.S. Lee, Clinical characteristics and follow-up of intracranial metastases from thyroid cancer. Acta Neurochir. (Wien.) 157(12), 2185–2194 (2015)CrossRef
19.
Zurück zum Zitat J. Simões-Pereira, Clinical outcomes of a cohort of patients with central nervous system metastases from thyroid cancer. Endocr. Connect. 5(6), 82–88 (2016)CrossRefPubMedPubMedCentral J. Simões-Pereira, Clinical outcomes of a cohort of patients with central nervous system metastases from thyroid cancer. Endocr. Connect. 5(6), 82–88 (2016)CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat I. Slutzky-Shraga, Clinical characteristics and disease outcome of patients with non-medullary thyroid cancer and brain metastases. Oncol. Lett. 15(1), 672–676 (2018)PubMed I. Slutzky-Shraga, Clinical characteristics and disease outcome of patients with non-medullary thyroid cancer and brain metastases. Oncol. Lett. 15(1), 672–676 (2018)PubMed
22.
Zurück zum Zitat R.J. Robbins, Real-time prognosis for metastatic thyroid carcinoma based on 2 –18 F fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J. Clin. Endocrinol. Metab. 91(2), 498–505 (2006)CrossRefPubMed R.J. Robbins, Real-time prognosis for metastatic thyroid carcinoma based on 2 –18 F fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J. Clin. Endocrinol. Metab. 91(2), 498–505 (2006)CrossRefPubMed
23.
Zurück zum Zitat L.Y. Wang, Multi-organ distant metastases confer worse disease-specific survival in differentiated thyroid cancer. Thyroid 24(11), 1594–1599 (2014)CrossRefPubMed L.Y. Wang, Multi-organ distant metastases confer worse disease-specific survival in differentiated thyroid cancer. Thyroid 24(11), 1594–1599 (2014)CrossRefPubMed
24.
Zurück zum Zitat A. Sabet, Distinguishing synchronous from metachronous manifestation of distant metastases: a prognostic feature in differentiated thyroid carcinoma. Eur. J. Nucl. Med Mol. Imaging 44(2), 190–195 (2017)CrossRefPubMed A. Sabet, Distinguishing synchronous from metachronous manifestation of distant metastases: a prognostic feature in differentiated thyroid carcinoma. Eur. J. Nucl. Med Mol. Imaging 44(2), 190–195 (2017)CrossRefPubMed
25.
Zurück zum Zitat J. Lee, Differentiated thyroid carcinoma presenting with distant metastasis at initial diagnosis. Clinical outcomes and prognostic factors. Ann. Surg. 251(1), 114–119 (2010)CrossRefPubMed J. Lee, Differentiated thyroid carcinoma presenting with distant metastasis at initial diagnosis. Clinical outcomes and prognostic factors. Ann. Surg. 251(1), 114–119 (2010)CrossRefPubMed
26.
Zurück zum Zitat F. Vaisman, A new appraisal of radiodine refractory thyroid cancer. Endocr. Relat. Cancer 22(6), R301–R310 (2015)CrossRefPubMed F. Vaisman, A new appraisal of radiodine refractory thyroid cancer. Endocr. Relat. Cancer 22(6), R301–R310 (2015)CrossRefPubMed
27.
Zurück zum Zitat F. Pitoia, Long-term survival and low effective cumulative dose of radioiodine doses to achieve remission in patients with 131Iodine-avid lung metastases from differentiated thyroid cancer. Clin. Nucl. Med. 39(9), 784–790 (2014)CrossRefPubMed F. Pitoia, Long-term survival and low effective cumulative dose of radioiodine doses to achieve remission in patients with 131Iodine-avid lung metastases from differentiated thyroid cancer. Clin. Nucl. Med. 39(9), 784–790 (2014)CrossRefPubMed
28.
Zurück zum Zitat I. Califano, Outcomes of patients with bone metastases from differentiated thyroid cancer. Arch. Endocrinol. Metab. 62(1), 14–20 (2018)CrossRefPubMed I. Califano, Outcomes of patients with bone metastases from differentiated thyroid cancer. Arch. Endocrinol. Metab. 62(1), 14–20 (2018)CrossRefPubMed
30.
Zurück zum Zitat S. Ginzburg, Papillary thyroid carcinoma metastases presenting as ipsilateral adrenal mass and renal cyst. Urol. Case Rep. 3(6), 221–222 (2015)CrossRefPubMedPubMedCentral S. Ginzburg, Papillary thyroid carcinoma metastases presenting as ipsilateral adrenal mass and renal cyst. Urol. Case Rep. 3(6), 221–222 (2015)CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat C. Brient, Differentiated thyroid cancer with liver metastases: lessons learned from managing a series of 14 patients. Int Surg. 100(3), 490–496 (2015)CrossRefPubMedPubMedCentral C. Brient, Differentiated thyroid cancer with liver metastases: lessons learned from managing a series of 14 patients. Int Surg. 100(3), 490–496 (2015)CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat B. Robinson, Characterization of tumor size changes over time from the phase 3 study in lenvatinib on thyroid cancer. J. Clin. Endocrinol. Metab. 101(11), 4103–4109 (2016)CrossRefPubMedPubMedCentral B. Robinson, Characterization of tumor size changes over time from the phase 3 study in lenvatinib on thyroid cancer. J. Clin. Endocrinol. Metab. 101(11), 4103–4109 (2016)CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat M.E. Cabanillas, Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the MD Anderson experience. J. Clin. Endocrinol. Metab. 95(6), 2588–2595 (2010)CrossRefPubMed M.E. Cabanillas, Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the MD Anderson experience. J. Clin. Endocrinol. Metab. 95(6), 2588–2595 (2010)CrossRefPubMed
Metadaten
Titel
Unusual metastases from differentiated thyroid carcinoma: analysis of 36 cases
verfasst von
Anabela Zunino
Fabián Pitoia
Eduardo Faure
Adriana Reyes
Mónica Sala
Rosana Sklate
Verónica Ilera
Inés Califano
on behalf of the Thyroid Department of Sociedad Argentina de Endocrinología y Metabolismo
Publikationsdatum
20.07.2019
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 3/2019
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-019-01991-0

Weitere Artikel der Ausgabe 3/2019

Endocrine 3/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.